Primmune Therapeutics
Carlsbad, US · 4 known investors
Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.
BiotechHealthtech
Investors · 4
Frequently asked questions
- What does Primmune Therapeutics do?
- Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.
- Who are Primmune Therapeutics's investors?
- Primmune Therapeutics's investors include BioBrit, BioRock Ventures, Samsara BioCapital, Polaris Partners.
- Where is Primmune Therapeutics headquartered?
- Primmune Therapeutics is headquartered in Carlsbad, US.